Home > Oncology > Large phase 3 trial tests novel combinations for metastatic RCC

Large phase 3 trial tests novel combinations for metastatic RCC

Expert
Prof. Toni Choueiri, Dana-Farber Cancer Institute, Harvard Medical School, MA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
KEYNOTE-581/CLEAR
An ongoing open-label, randomised phase 3 trial (NCT04736706) will determine the efficacy of the triplet combinations of belzutifan, lenvatinib, and pembrolizumab or lenvatinib, pembrolizumab, and quavonlimab versus lenvatinib and pembrolizumab alone, for the treatment of advanced clear cell renal cell carcinoma (ccRCC), according to a presentation at ASCO’s Genitourinary Cancers Symposium (GU22), held in San Francisco, CA from 17-19 February, 2022 [1]. Medicom attended GU22 and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on